Pyxis Oncology, Inc. (PYXS)

NASDAQ: PYXS · USD

$1.98

+0.14 (+7.6%)· Recorded snapshot

Market cap	236.5M
Revenue (ttm)	11M
Net income (ttm)	-88.7M
EPS (ttm)	-$1.40
Shares out	119.5M
Volume	676,430
Beta	1.38

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 11M
Net income (ttm): -88.7M
EPS (ttm): -$1.40
Market cap: 236.5M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-179.1

P25 n/aP50 n/aP75 n/a

ROIC-82.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All PYXS indicators

Market & fundamental data

Available fields

196

Groups with data

Currency

USD

Showing 196 of 196 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001782223
Company name	Pyxis Oncology, Inc.
Country	United States
Country code	US
CUSIP number	747324101
Earnings date	2026-11-10
Earnings time	bmo
Employees	56
Employees change	12
Employees growth	27.27%
Enterprise value	$221.4M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2018
Industry	Biotechnology
IPO date	2021-10-01
Is primary listing	Yes
Is SPAC	No
ISIN number	US7473241013
Last 10-K release date	2026-03-23
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$236.5M
Market cap category	Micro-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$1.98
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	PYXS
U.S. state	Massachusetts
Website	https://www.pyxisoncology.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-70.85%
EV/Sales	19.24x
FCF / EV yield	-31.98%
FCF yield	-29.85%
Forward EV/Sales	10,925.91x
Forward P/S	11,705.95x
P/B ratio	10.2x
P/S ratio	20.62x
Price / tangible book value	19.89x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	78.37%
Operating margin	-812.74%
Pretax margin	-793.84%
Profit per employee	$-1.6M
Revenue per employee	$197,107
ROA	-62.95%
ROA (5Y)	-30.69%
ROCE	-326.84%
ROE	-179.1%
ROE (5Y)	-63.93%
ROIC	-82.23%
SBC / revenue	107.75%
Tax / revenue	9.99%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	5
Gross profit growth	206.74%
Net income growth years	0
Revenue growth	291.42%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-9,000
Depreciation and amortization	$4.2M
EBIT	$-89.7M
EBITDA	$-85.5M
EPS	$-1.40
FCF per share	$-0.57
Financing cash flow	$10.6M
Free cash flow	$-67.9M
Free cash flow minus SBC	$-79.8M
Gross profit	$8.7M
Income taxes	$1.1M
Investing cash flow	$65.4M
Net cash flow	$8.1M
Net income	$-88.7M
Operating cash flow minus SBC	$-79.8M
Operating income	$-89.7M
Revenue	$11M
Stock-based compensation	$11.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-15.71
Book value per share	$0.18
Debt / equity	1.56
Long-term assets	$18.2M
Long-term liabilities	$16M
Net cash (debt)	$15.2M
Net cash / market cap	6.66%
Net cash growth	-78.18%
Net debt / equity	-1.33
Piotroski F-Score	2
Property, plant and equipment	$18.2M
Shareholders' equity	$11.4M
Tangible book value	$11.4M
Tangible book value per share	$0.18
Total assets	$54.9M
Total cash	$33M
Total debt	$17.8M
Total liabilities	$43.5M
WACC	10.97%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.12
Current assets	$36.7M
Current liabilities	$27.5M
Current ratio	1.34
Net working capital	$-21.9M
Quick ratio	1.2
Working capital	$9.3M
Working capital turnover	0.24

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-3.27%
Dividend yield	0%
Shareholder yield	-3.27%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$2.37
1D price change	7.61%
1M price change	-33.22%
1M total return	-33.22%
1W price change	3.8%
1W total return	3.8%
1Y price change	-43.66%
1Y return CAGR	-43.68%
1Y total return	-43.66%
20-day SMA	$1.90
200-day SMA	$2.16
3M price change	-34.36%
3M total return	-34.36%
3Y price change	21.66%
3Y return CAGR	6.75%
3Y total return	21.66%
50-day SMA	$2.71
50-day SMA vs 200-day SMA	50over200
52-week high	$5.55
52-week high date	2025-11-26
52-week low	$1.03
52-week low date	2025-12-26
5Y price change	-85.3%
5Y return CAGR	-31.85%
5Y total return	-85.3%
6M price change	8.52%
6M total return	8.52%
All-time high	$19.00
All-time high date	2021-10-08
All-time low	$0.83
All-time low date	2025-04-07
Average true range (ATR)	$0.17
Average volume	1.1M
Beta (1Y)	2.91
Beta (2Y)	1.68
Beta (5Y)	1.38
Change from 52-week high	-64.32%
Change from 52-week low	92.23%
Change from all-time high	-89.95%
Change from all-time low	129.24%
Change from open	7.03%
Day's gap	0.54%
Dollar volume	$1.3M
High price	$1.98
Low price	$1.81
Monthly RSI	45.97
Open price	$1.85
Position in 52-week range	100%
Premarket change	1.63%
Premarket close	$1.84
Premarket price	$1.87
Premarket volume	18K
Previous close	$1.84
Price vs 150-day SMA	-19.41%
Price vs 20-day SMA	0.69%
Price vs 200-day SMA	-11.53%
Price vs 50-day SMA	-29.55%
Relative volume	0.64
Return from IPO price	-88.09%
RSI	40.67
Sharpe ratio	0.18
Sharpe ratio (3Y)	0.57
Sharpe ratio (5Y)	0.12
Sortino ratio	0.3
Sortino ratio (3Y)	0.91
Sortino ratio (5Y)	0.24
Volume	676.4K
Weekly RSI	44.29
YTD price change	66.09%
YTD total return	66.09%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	78.3M
Float percentage	65.58%
Shares change (QoQ)	0.82%
Shares change (YoY)	3.27%
Shares held by insiders	3.56%
Shares held by institutions	14.49%
Shares outstanding	119.5M
Short % of float	6.24%
Short % of shares	4.09%
Short ratio	4 days

Deeper analysis on PYXS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this PYXS report

Is a complete PYXS research report available?

No complete published report is available for Pyxis Oncology, Inc. (PYXS) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Pyxis Oncology, Inc. (PYXS)

Price

Financial snapshot

Fair-value bridge

Latest news · PYXS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All PYXS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on PYXS

Frequently asked questions